PubHawk
Nat Med December 2025 PMID 41057655

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.

Gerhardt Attard, Neeraj Agarwal, Julie N Graff, Shahneen Sandhu, Eleni Efstathiou, Mustafa Özgüroğlu, Andrea J Pereira de Santana Gomes, Karina Vianna, Hong Luo, Geoffrey T Gotto, Heather H Cheng, Won Kim, Carly R Varela, Daneen Schaeffer, Kassie Kramer

Download social card

Mentions

136
Peak: 11 in Oct 2025
across 8 sources since Oct 2025

Extended reach

31,939
potential audience

Total likes

16

Video views

203

Mentions per month

Oct 2025 – Oct 2026

Where it's discussed

  • News52 articles
  • Facebook34 posts
  • LinkedIn28 posts
  • Instagram8 posts
  • X / Twitter7 posts
  • Bluesky5 posts
  • YouTube1 videos
  • Blogs1 articles

AI synopsis

What people are saying

Multiple mentions, such as the extensive coverage of the trial results in Nature Medicine and news outlets, demonstrate high interest and impact; tone varies from clinical and factual to promotional, highlighting the therapy’s potential benefits and risks. For example, mentions emphasize how the drug combination delays disease progression, while others discuss genetic testing's role, supporting the view that the study could alter treatment standards.

AgreementModerate agreement

Most mentions recognize the significance of the study's findings; some express strong support or highlight its importance.

InterestHigh interest

Mentions show high curiosity about the combination therapy, gene testing, and clinical implications, indicating strong interest.

EngagementModerate engagement

Mentions often discuss details like survival benefits, risks, and genetic testing, reflecting engagement with methods and implications.

ImpactHigh impact

The widespread attention from news outlets, professional discussions, and clinical trials suggests high impact on medical practice and research.

Abstract in brief

  • The study tested whether adding niraparib, a PARP inhibitor, to standard treatment with abiraterone acetate and prednisone (AAP) could improve outcomes for patients with metastatic castration-sensitive prostate cancer (mCSPC) who have HRR gene alterations, especially within 6 months of hormone therapy start.
  • Results showed that in patients with BRCA1/BRCA2 or other HRR gene alterations, this combination significantly extended radiographic progression-free survival (median not reached versus 26 months for AAP alone), with a hazard ratio of 0.52 in the BRCA subgroup and 0.63 overall, indicating a reduction in progression risk.
  • However, the combination also increased adverse events, with 75% of patients experiencing grade 3 or 4 side effects (mainly anemia and hypertension), and there were 14 treatment-related deaths in the niraparib group compared to 7 in the placebo group, highlighting the balance between potential benefits and risks.]
Read the full abstract

Top posts

Most liked on X and Bluesky
Wafik S. El-Deiry, MD, PhD, FACP
@weldeiry · X

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial https://t.co/f4UI17Yee6

Oct 21, 2025 · 6 likes · 2 shares · 22,093 followers View post →
Álvaro Pinto
@dralvaropinto · X

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial | Nature Medicine https://t.co/XL4RalnLGm

Oct 8, 2025 · 3 likes · 3,591 followers View post →
Stuart Edmonds (he/him)
@stuart365.bsky.social · Bluesky

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial in @natmed.nature.com www.nature.com/articles/s41...

Oct 8, 2025 · 1 like View post →
STITCHES Medicine - the Best of Medical Research
@medicine.stitches.today · Bluesky

Niraparib plus abiraterone significantly boosts radiographic progression-free survival in metastatic castration-sensitive prostate cancer with HRR gene alterations. by Attard G, Agarwal N (...) Rathkopf DE et 20 al. in Nat Med #MedSky ? get more here ? read the article:

Oct 16, 2025 · 1 like · 1 share View post →
Boris Hadaschik
@hadaschik.bsky.social · Bluesky

AMPLITUDE finally published. Congratulations to all involved www.nature.com/articles/s41...

Oct 8, 2025 · 1 like View post →
Dr. Gennadi Glinsky, MD, Ph.D.
@gglinskii · X

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial https://t.co/rOlT4wel0B

Oct 9, 2025 · 1,973 followers View post →

All mentions

Dr Akhil Santhosh MD DM MRCP(UK)
@tuttsakhil · X

Re: Niraparib and Abiraterone Acetate plus Prednisone for HRR-deficient Metastatic Castration-sensitive Prostate Cancer: A Randomized Phase 3 Trial - @EurUrolOncol https://t.co/pwLUmXjM9B

Dec 17, 2025 · 1,115 followers View post →
Samuel Lewis
@saminnomedai · X

RT @weldeiry: Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a random…

Oct 21, 2025 · 2 shares · 38 followers View post →
G.Wenger
@bricolix · X

RT @weldeiry: Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a random…

Oct 21, 2025 · 2 shares · 1,476 followers View post →
Wafik S. El-Deiry, MD, PhD, FACP
@weldeiry.bsky.social · Bluesky

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial www.nature.com/articles/s41...

Oct 21, 2025 View post →
Wafik S. El-Deiry, MD, PhD, FACP
@weldeiry · X

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial https://t.co/f4UI17Yee6

Oct 21, 2025 · 6 likes · 2 shares · 22,093 followers View post →
STITCHES Medicine - the Best of Medical Research
@medicine.stitches.today · Bluesky

Niraparib plus abiraterone significantly boosts radiographic progression-free survival in metastatic castration-sensitive prostate cancer with HRR gene alterations. by Attard G, Agarwal N (...) Rathkopf DE et 20 al. in Nat Med #MedSky ? get more here ? read the article:

Oct 16, 2025 · 1 like · 1 share View post →
Climate, Ecology, War & More: Dr. Glen Barry BigEarthData.ai
@bigearthdata.ai · Bluesky

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial ->Nature | More from Lil' Dr Glen at BigEarthData.ai

Oct 10, 2025 View post →
Life Science Journal Content
@lsn_jc · X

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial #science #publication #research #journal https://t.co/CPBeD8xl7z

Oct 10, 2025 · 197 followers View post →
Dr. Gennadi Glinsky, MD, Ph.D.
@gglinskii · X

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial https://t.co/rOlT4wel0B

Oct 9, 2025 · 1,973 followers View post →
Stuart Edmonds (he/him)
@stuart365.bsky.social · Bluesky

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial in @natmed.nature.com www.nature.com/articles/s41...

Oct 8, 2025 · 1 like View post →
Álvaro Pinto
@dralvaropinto · X

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial | Nature Medicine https://t.co/XL4RalnLGm

Oct 8, 2025 · 3 likes · 3,591 followers View post →
Boris Hadaschik
@hadaschik.bsky.social · Bluesky

AMPLITUDE finally published. Congratulations to all involved www.nature.com/articles/s41...

Oct 8, 2025 · 1 like View post →
Expanding indications for PARP inhibitors in prostate cancer
News

Özgüroğlu, et al. Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 ...

Oct 17, 2026 View →
Evolving Sequencing Strategies for PARP Inhibitors in BRCA ...
News

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial. Nat Med ...

Oct 17, 2026 View →
AMPLITUDE Study - AKEEGA® - J&J Medical Connect
News

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial. Nat Med ...

Oct 17, 2026 View →
Niraparib Plus Abiraterone and Prednisone Improves Radiographic ...
News

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial. Nature Medicine, Published online: 2025-10-07; | doi:10.1038/s41591-025-03961-8Attard et al.2025.

Oct 17, 2026 View →
Current poly(adenosine diphosphate–ribose) polymerase inhibitors ...
News

doi: 10.1038/s41591-025-03961-8. (Open in a new window)PubMed (Open in a new window)Web of Science ®(Open in a new window)Google Scholar. Agarwal N, Matsubara ...

Oct 17, 2026 View →
Shahneen Sandhu - ORCID
News

10.1038/s41591-025-03961-8. Contributors: Gerhardt Attard; Neeraj Agarwal; Julie N. Graff; Shahneen Sandhu; Eleni Efstathiou; Mustafa Özgüroğlu; Andrea J ...

Oct 17, 2026 View →
Impact of homologous recombination repair gene mutations on ...
News

, 10.1038/s41591-025-03961-8 · View in Scopus Google Scholar. [7]. K.N. Chi, S. Sandhu, M.R. Smith, G. Attard, M. Saad, D. Olmos, et al. Niraparib plus ...

Oct 17, 2026 View →
The role of molecular profiling for castration-resistant prostate ...
News

. 10.1038/s41591-025-03961-8. CrossRef · Google Scholar; View reference in article. 10. BeltranH.OromendiaC.DanilaD. C.MontgomeryB.HoimesC.SzmulewitzR. Z.et al ...

Oct 17, 2026 View →
Evolent Clinical Guideline 3200 for AkeegaTM (niraparib and ...
News

doi: 10.1038/s41591-025-03961-8. 2. Chi KN, et al; MAGNITUDE Principal Investigators. Niraparib and Abiraterone Acetate for. Metastatic Castration-Resistant ...

Oct 17, 2026 View →
Niraparib + abiraterone acetate - ESMO-MCBS Scorecards | ESMO
News

doi:10.1038/s41591-025-03961-8. Disclaimer. ESMO-MCBS scores are based on peer reviewed clinical trial reports. They are generated using a validated standard ...

Oct 17, 2026 View →
Study Details | NCT04497844 - ClinicalTrials.gov
News

doi: 10.1038/s41591-025-03961-8. Epub 2025 Oct 7.(https://pubmed.ncbi.nlm.nih.gov/41057655). Study Record Dates. These dates track the progress of study ...

Oct 17, 2026 View →
AKEEGA® (niraparib/abiraterone acetate) Healthcare Professional ...
News

doi:10.1038/s41591-025-03961-8. INDICATION. AKEEGA® is a combination of niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a ...

Oct 17, 2026 View →
Rusia registró Elefusa (fuzuloparib), un nuevo tratamiento dirigido a ...
Facebook

... 10.1038/s41591-025-03961-8 Fuente: Ciencia, Astronomía y Afines · No photo description available. Deysi Querevalu Ramires and Golden Hawk. 2 ...

Oct 11, 2026 View →
Ulrike Harjes' Post - LinkedIn
LinkedIn

New out in #NatureMedicine Nature Portfolio Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration ...

Oct 5, 2026 View →
Integrating Talazoparib Plus Enzalutamide Into HRR-Mutated ...
News

... 10.1038/s41591-025-03961-8. Newsletter. Stay up to date on recent advances in the multidisciplinary approach to cancer. Email address.

Sep 29, 2026 View →
Una nueva vía de investigación busca frenar la metástasis del ...
Facebook

... 10.1038/s41591-025-03961-8 Fuente: Ciencia, Astronomía y Afines · No photo description available. Deysi Querevalu Ramires and Golden Hawk. 2 ...

Sep 28, 2026 View →
A Study of Niraparib in Combination With Abiraterone Acetate and ...
News

doi: 10.1038/s41591-025-03961-8. Epub 2025 Oct 7. PubMed 41057655. Investigators. Sponsor: Janssen Research & Development, LLC. Sponsor Class ...

Sep 28, 2026 View →
ancap - Facebook
Facebook

... 10.1038/s41591-025-03961-8 Fuente: Ciencia, Astronomía y Afines · No photo description available. Deysi Querevalu Ramires and Golden Hawk. 2 ...

Sep 23, 2026 View →
Una combinación de fármacos mejora la respuesta en cáncer de ...
Facebook

... 10.1038/s41591-025-03961-8 Fuente: Ciencia, Astronomía y Afines · No photo description available. Deysi Querevalu Ramires and Golden Hawk. 2 ...

Sep 21, 2026 View →
A Phase II Study of Berzosertib in Combination with Carboplatin ...
News

https://doi.org/10.1038/s41591-025-03961-8 . Google Scholar · Crossref · Search ADS · PubMed. 7. Agarwal. N. ,. Azad. AA. ,. Carles. J. ,. Fay.

Sep 18, 2026 View →
Prostate Cancer ASCO 2026: Biomarkers & Perioperative Care
News

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer (AMPLITUDE). Presented ...

Sep 15, 2026 View →
Si tú o alguien cercano convive con un cáncer de riñón avanzado ...
Facebook

... 10.1038/s41591-025-03961-8 Fuente: Ciencia, Astronomía y Afines · No photo description available. Deysi Querevalu Ramires and Golden Hawk. 2 ...

Sep 14, 2026 View →
Científicos descubren los procesos que dañan el ADN en la mayoría ...
Facebook

... 10.1038/s41591-025-03961-8 Fuente: Ciencia, Astronomía y Afines · No photo description available. Deysi Querevalu Ramires and Golden Hawk. 2 ...

Sep 9, 2026 View →
reconoce el PSMA presente en muchas células del cáncer de ...
Facebook

... 10.1038/s41591-025-03961-8 Fuente: Ciencia, Astronomía y Afines · No photo description available. Deysi Querevalu Ramires and Golden Hawk. 2 ...

Sep 5, 2026 View →
European Commission approves AKEEGA (niraparib and ...
News

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.

Sep 3, 2026 View →
Investigadores de la Universidad de Michigan (Estados Unidos) han ...
Facebook

... 10.1038/s41591-025-03961-8 Fuente: Ciencia, Astronomía y Afines · No photo description available. Deysi Querevalu Ramires and Golden Hawk. 2 ...

Aug 26, 2026 View →
O custo do tempo: diagnóstico precoce é a chave para salvar o ...
Instagram

https://doi.org/10.1038/s41591-025-03961-8 · Agarwal N et al. Lancet 2023;402(10398):291-303. https://doi.org/10.1016/S0140-6736(23)01055-3

Aug 13, 2026 View →
BIO | O Dr. Fernando Sabino recebe os Drs. Andrey Soares, Adriano ...
Instagram

https://doi.org/10.1038/s41591-025-03961-8 · Agarwal N et al. Lancet 2023;402(10398):291-303. https://doi.org/10.1016/S0140-6736(23)01055-3

Jul 28, 2026 View →
A genética chegou à primeira linha do câncer de próstata ...
Instagram

... 10.1038/s41591-025-03961-8 · Agarwal N et al. Lancet 2023;402(10398):291-303. https://doi.org/10.1016/S0140-6736(23)01055-3 #Urologia ...

Jul 21, 2026 View →
lessons from PEACE-3 and BRCAaway in the post-ARPI era
News

https://doi.org/10.1038/ · s41591-025-03961-8. © The Author(s) 2026. Published by Oxford University Press. This is an Open Access article ...

Jul 9, 2026 View →
TALAPRO-3研究开启mHSPC精准治疗新篇章，HRR基因检测亟待前移
News

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 ...

Jul 7, 2026 View →
Treatment Patterns and Attrition in Metastatic Castration-Resistant ...
News

doi:10.1038/s41591-025-03961-8 PubMedGoogle ScholarCrossref. 43. Tagawa ST, Sartor O, Piulats JM, et al. LBA6 phase III trial of [177Lu] ...

Jun 29, 2026 View →
La nueva combinación de medicamentos que mejora el tratamiento ...
Facebook

... 10.1038/s41591-025-03961-8 Fuente: Ciencia, Astronomía y Afines · No photo description available. Deysi Querevalu Ramires and Golden Hawk. 2 ...

Jun 22, 2026 View →
Advancing metastatic prostate cancer care: best practices and future ...
News

Ozguroglu, et al. Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a ...

Jun 13, 2026 View →
Dr. Tanya Dorff & Dr. Evan Yu | Ep. 307 - YouTube
YouTube

... Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 ...

Jun 9, 2026 View →
Investigadores del Centro Médico Irving de la Universidad de ...
Facebook

... 10.1038/s41591-025-03961-8 Fuente: Ciencia, Astronomía y Afines · No photo description available. Deysi Querevalu Ramires and Golden Hawk. 2 ...

Jun 2, 2026 View →
PARPi-Palooza: Sorting out the Many Options in Prostate Cancer
News

doi: 10.1038/s41591-025-03961-8. Epub 2025 Oct 7. PMID: 41057655; PMCID: PMC12705445. Agarwal N, Matsubara N, et al. PARP and androgen ...

Jun 1, 2026 View →
El Periódico - Facebook
Facebook

... 10.1038/s41591-025-03961-8 Fuente: Ciencia, Astronomía y Afines · No photo description available. Deysi Querevalu Ramires and Golden Hawk. 2 ...

May 31, 2026 View →
La combinación del inhibidor de andrógenos enzalutamida y del ...
Facebook

... 10.1038/s41591-025-03961-8 Fuente: Ciencia, Astronomía y Afines · No photo description available. Deysi Querevalu Ramires and Golden Hawk. 2 ...

May 31, 2026 View →
Investigadores identifican un gen que impulsa el desarrollo del ...
Facebook

... 10.1038/s41591-025-03961-8 Fuente: Ciencia, Astronomía y Afines · No photo description available. Deysi Querevalu Ramires and Golden Hawk. 2 ...

May 29, 2026 View →
AUA 2026: Advanced Prostate Cancer - Doublet Versus Triplet
News

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: A randomized phase 3 trial.

May 18, 2026 View →
Swedish PRecision medicine Initiative for Novel Treatments and ...
News

DOI: https://doi.org/10.1038/s41591-025-03961-8. Fizazi K, Clarke NW, De Santis M, Uemura H, Fay AP, Karadurmus N, et al. Capivasertib plus ...

May 4, 2026 View →
APCCC 2026: Which Patients Should Receive "TRIPLET and More ...
News

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: A randomized phase 3 trial.

May 2, 2026 View →
APCCC 2026: How to Select Patients with mHSPC for ADT plus an ...
News

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: A randomized phase 3 trial.

May 2, 2026 View →
European Urology-April 2026 - Scribd
News

Re: Niraparib and Abiraterone Acetate plus Prednisone for HRR-deficient Metastatic 386. Castration-sensitive Prostate Cancer: A Randomized ...

Apr 16, 2026 View →
EAU 2026: PARPi in mHSPC or Should We Wait Until mCRPC?
News

doi: 10.1038/s41591-025-03961-8. Epub 2025 Oct 7. PMID: 41057655; PMCID: PMC12705445. Chi KN, Rathkopf DE, Smith MR, Efstathiou E, Attard G ...

Mar 16, 2026 View →
State of the Art Lecture: PARP Inhibitors in mHSPC and mCRPC
News

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: A randomized phase 3 trial.

Mar 16, 2026 View →
La Commission européenne approuve AKEEGA® (comprimé à
News

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.

Mar 11, 2026 View →
Niraparib and Abiraterone Acetate Nets European Approval in ...
News

... 10.1038/s41591-025-03961-8; FDA approves niraparib and abiraterone acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive ...

Mar 10, 2026 View →
European Commission approves AKEEGA® (niraparib and ...
News

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.

Mar 9, 2026 View →
European Commission approves AKEEGA® (niraparib and ...
News

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.

Mar 9, 2026 View →
Was wäre, wenn Krebs an seiner eigenen DNA scheitert ... - Instagram
Instagram

42 likes, 2 comments - thorstenschlomm on March 6, 2026: "Was wäre, wenn Krebs an seiner eigenen DNA scheitert? Genau das versucht eine neue ...

Mar 6, 2026 View →
Johnson & Johnson erhält vom CHMP einen positiven Bescheid
News

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.

Feb 6, 2026 View →
Johnson & Johnson receives CHMP positive opinion for AKEEGA ...
News

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.

Feb 1, 2026 View →
Johnson & Johnson receives CHMP positive opinion for
News

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.

Jan 30, 2026 View →
Johnson & Johnson receives CHMP positive opinion for AKEEGA ...
News

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.

Jan 30, 2026 View →
Colegio Mexicano de Urología Nacional A. C. - Facebook
Facebook

... 10.1038/s41591-025-03961-8 Fuente: Ciencia, Astronomía y Afines · No photo description available. Deysi Querevalu Ramires and Golden Hawk. 2 ...

Jan 8, 2026 View →
Una Publicación Repost @lacarabuenadelmundo Una nueva y ...
Instagram

... 10.1038/s41591-025-03961-8; ClinicalTrials.gov identifier: NCT04497844 . #Saludybienestar #Cáncer #Cancer #cancerprostata #Microbiologia ...

Dec 26, 2025 View →
Public Health PR - Facebook
Facebook

Referencias: - "Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a ...

Dec 15, 2025 View →
FDA Approves Niraparib Regimen in BRCA2+ Metastatic CSPC
News

... 10.1038/s41591-025-03961-8. Newsletter. Stay up to date on recent advances in the multidisciplinary approach to cancer. Email address.

Dec 12, 2025 View →
Prof Dr Canfeza Sezgin on Instagram: "UCL liderliğindeki büyük bir ...
Instagram

... Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 ...

Dec 8, 2025 View →
UCL liderliğindeki büyük bir uluslararası çalışma, agresif ... - Facebook
Facebook

... Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 ...

Dec 8, 2025 View →
Neste Novembro Azul, destacamos mais uma vez um avanço da ...
Instagram

https://doi.org/10.1038/s41591-025-03961-8 · Agarwal N et al. Lancet 2023;402(10398):291-303. https://doi.org/10.1016/S0140-6736(23)01055-3

Nov 5, 2025 View →
Miguel Bronchud's Post - LinkedIn
LinkedIn

... Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 ...

Oct 27, 2025 View →
Combining Niraparib with Abiraterone Acetate and Prednisone ...
News

DOI: https://doi.org/10.1038/s41591-025-03961-8. Legal. Terms of Use · Privacy Policy; Change cookie settings. Useful links. About ESMO ...

Oct 22, 2025 View →
Doctors just found a way to slow one of the deadliest prostate cancers
News

Nature Medicine, 2025; DOI: 10.1038/s41591-025-03961-8. Cite This Page: MLA; APA; Chicago. University College London. "Doctors just found a way ...

Oct 21, 2025 View →
AMPLITUDE: HRQOL is maintained with niraparib plus abiraterone
News

... Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 ...

Oct 21, 2025 View →
PDAC: ADCs and Oncolytic Viruses at ESMO 2025 - LinkedIn
LinkedIn

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.

Oct 21, 2025 View →
New Drug Combination Found to Slow One of the Deadliest Forms ...
News

Chi and Dana E. Rathkopf, 7 October 2025, Nature Medicine. DOI: 10.1038/s41591-025-03961-8. Never miss a breakthrough: Join the SciTechDaily ...

Oct 20, 2025 View →
Los hombres cuyo cáncer de próstata regresa después ... - Facebook
Facebook

... 10.1038/s41591-025-03961-8 Fuente: Ciencia, Astronomía y Afines · No photo description available. Deysi Querevalu Ramires and Golden Hawk. 2 ...

Oct 20, 2025 View →
PARP Inhibitor Combo Shows Promising Efficacy in HRR-Altered ...
News

... 10.1038/s41591-025-03961-8. 2. FDA approves niraparib and abiraterone acetate plus prednisone for BRC. FDA. August 11, 2023. Accessed October ...

Oct 14, 2025 View →
Niraparib Combo Boosts rPFS in Metastatic HRR-Altered CSPC
News

... 10.1038/s41591-025-03961-8; New drug combination offers hope for men with advanced prostate cancer. News release. University College London ...

Oct 12, 2025 View →
un médicament prometteur pourrait freiner le cancer de la prostate ...
News

Source : Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized ...

Oct 9, 2025 View →
Novel Drug Combo Improves Survival in Patients With Metastatic ...
News

... 10.1038/s41591-025-03961-8. 2. A study of niraparib in combination with abiraterone acetate and prednisone versus abiraterone acetate and ...

Oct 8, 2025 View →
New drug combination could delay the progression of advanced ...
Blogs

doi.org/10.1038/s41591-025-03961-8. Currently rated 5.0 by 1 person. Posted in: Men's Health News | Drug Trial News. Comments (0). Download PDF ...

Oct 7, 2025 View →
Novel drug combination offers hope for men with advanced prostate ...
News

DOI: 10.1038/s41591-025-03961-8. Journal information: Nature Medicine. Key medical concepts. Prostate Carcinomaniraparib. Clinical categories.

Oct 7, 2025 View →
New drug combination offers hope for men with advanced prostate ...
News

DOI: https://doi.org/10.1038/s41591-025-03961-8. About UCL – London's Global University. UCL is a diverse global community of world-class ...

Oct 7, 2025 View →
Published data show benefit of niraparib with AAP in HRR-deficient ...
News

... 10.1038/s41591-025-03961-8. 2. New drug combination offers hope for men with advanced prostate cancer. News release. University College ...

Oct 7, 2025 View →
FDA grants Fast Track status to ETX-636 for PIK3CA-mutant breast ...
LinkedIn

New out in #NatureMedicine Nature Portfolio Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration ...

Oct 1, 2025 View →
ETX-636 granted Fast Track designation by FDA for breast cancer ...
LinkedIn

New out in #NatureMedicine Nature Portfolio Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration ...

Oct 1, 2025 View →
Natural compounds boost cancer therapy with metabolic ... - LinkedIn
LinkedIn

... Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 ...

Sep 27, 2025 View →
OUHospitals trials new treatments for myeloma - LinkedIn
LinkedIn

New out in #NatureMedicine Nature Portfolio Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration ...

Sep 22, 2025 View →
FDA grants breakthrough device designation to urine test for bladder ...
LinkedIn

New out in #NatureMedicine Nature Portfolio Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration ...

Sep 16, 2025 View →
BiVictriX Therapeutics reports preclinical results for BVX001, a ...
LinkedIn

... Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 ...

Sep 2, 2025 View →
FDA Approves 3-Month Leuprolide for Advanced Prostate Cancer
LinkedIn

... Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 ...

Aug 29, 2025 View →
EMA Authorizes Ayvakyt for Rare Gastrointestinal and Blood Cancers
LinkedIn

... Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 ...

Aug 6, 2025 View →
Chemotherapy, Targeted Therapy, Stem Cell Transplant, More
LinkedIn

... Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 ...

Jul 27, 2025 View →
Publicados en The Lancet, los resultados del ensayo de fase 3 ...
Facebook

... 10.1038/s41591-025-03961-8 Fuente: Ciencia, Astronomía y Afines · No photo description available. Deysi Querevalu Ramires and Golden Hawk. 2 ...

Jul 24, 2025 View →
Peptron's Leupone approved in Korea, challenges Takeda in ...
LinkedIn

... Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 ...

Jul 15, 2025 View →
Webinar: DPYD testing for fluoropyrimidine dosing in cancer care
LinkedIn

... Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 ...

Jul 14, 2025 View →
Imatinib: A Revolutionary Drug in Oncology History - LinkedIn
LinkedIn

... Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 ...

Jul 8, 2025 View →
Una nueva combinación de fármacos muestra beneficios en ...
Facebook

... 10.1038/s41591-025-03961-8 Fuente: Ciencia, Astronomía y Afines · No photo description available. Deysi Querevalu Ramires and Golden Hawk. 2 ...

Jul 7, 2025 View →
Oxygen Levels Alter Mitomycin C Efficacy in Ovarian Cancer ...
LinkedIn

... Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 ...

Jul 1, 2025 View →
4SC AG Secures Orphan Status for Resminostat in Liver Cancer ...
LinkedIn

... Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 ...

Jun 5, 2025 View →
Descubren un factor temprano de agresividad en el cáncer de próstata
Facebook

... 10.1038/s41591-025-03961-8 Fuente: Ciencia, Astronomía y Afines · No photo description available. Deysi Querevalu Ramires and Golden Hawk. 2 ...

Jun 2, 2025 View →
New compound may protect heart from Doxorubicin - LinkedIn
LinkedIn

... Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 ...

Apr 25, 2025 View →
Health-related quality of life and economic impacts in adults with ...
News

https://doi.org/10.1038/s41591-024-02827-9 · Article CAS PubMed Google ... https://doi.org/10.1007/s11136-025-03961-8. Download citation.

Apr 17, 2025 View →
TIL therapies: A new hope for cancer patients - LinkedIn
LinkedIn

... Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 ...

Apr 10, 2025 View →
ICUA - Instituto de Cirugía Urológica Avanzada - Facebook
Facebook

... 10.1038/s41591-025-03961-8 Fuente: Ciencia, Astronomía y Afines · No photo description available. Deysi Querevalu Ramires and Golden Hawk. 2 ...

Mar 6, 2025 View →
BCR-ABL1 fusion in CML and ALL: differences and implications
LinkedIn

... Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 ...

Feb 24, 2025 View →
Más de 800 pacientes con cáncer de próstata metastático ...
Facebook

... 10.1038/s41591-025-03961-8 Fuente: Ciencia, Astronomía y Afines · No photo description available. Deysi Querevalu Ramires and Golden Hawk. 2 ...

Feb 22, 2025 View →
William Hanley's Post - LinkedIn
LinkedIn

... Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 ...

Feb 13, 2025 View →
Instituto Oncológico Dr Rosell - Facebook
Facebook

... 10.1038/s41591-025-03961-8 Fuente: Ciencia, Astronomía y Afines · No photo description available. Deysi Querevalu Ramires and Golden Hawk. 2 ...

Feb 5, 2025 View →
Xinxin Song's Post - LinkedIn
LinkedIn

New out in #NatureMedicine Nature Portfolio Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration ...

Jan 15, 2025 View →
Heidi Haikala's Post - LinkedIn
LinkedIn

... Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 ...

Jan 9, 2025 View →
Ahmed Darwish's Post - LinkedIn
LinkedIn

New out in #NatureMedicine Nature Portfolio Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration ...

Dec 28, 2024 View →
Shushan Hovsepyan's Post - LinkedIn
LinkedIn

New out in #NatureMedicine Nature Portfolio Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration ...

Dec 17, 2024 View →
LifeSci Startup's Post - LinkedIn
LinkedIn

... Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 ...

Dec 5, 2024 View →
Shoufu Lu's Post - LinkedIn
LinkedIn

... Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 ...

Nov 20, 2024 View →
Chronetyx Laboratories' Post - LinkedIn
LinkedIn

... Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 ...

Nov 11, 2024 View →
#Investigación I Un equipo interdisciplinario está explorando cómo ...
Facebook

... 10.1038/s41591-025-03961-8 Fuente: Ciencia, Astronomía y Afines · No photo description available. Deysi Querevalu Ramires and Golden Hawk. 2 ...

Nov 6, 2024 View →
Feasibility of Indirect Treatment Comparisons Between Niraparib ...
News

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.

Jul 3, 2024 View →
Para algunos pacientes con cáncer de próstata metastásico, en ...
Facebook

... 10.1038/s41591-025-03961-8 Fuente: Ciencia, Astronomía y Afines · No photo description available. Deysi Querevalu Ramires and Golden Hawk. 2 ...

Jun 15, 2024 View →
Demonstrating Bioequivalence for Two Dose Strengths of Niraparib ...
News

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.

Mar 4, 2024 View →
Uso del selpercatinib para el cáncer de tiroides medular y de pulmón
Facebook

... 10.1038/s41591-025-03961-8 Fuente: Ciencia, Astronomía y Afines · No photo description available. Deysi Querevalu Ramires and Golden Hawk. 2 ...

Jan 4, 2024 View →
Cáncer de ovario avanzado: Olaparib + bevacizumab y ... - Facebook
Facebook

... 10.1038/s41591-025-03961-8 Fuente: Ciencia, Astronomía y Afines · No photo description available. Deysi Querevalu Ramires and Golden Hawk. 2 ...

Sep 13, 2022 View →
La FDA ha aprobado la terapia con 177Lu-PSMA-617 (LuPSMA
Facebook

... 10.1038/s41591-025-03961-8 Fuente: Ciencia, Astronomía y Afines · No photo description available. Deysi Querevalu Ramires and Golden Hawk. 2 ...

Mar 24, 2022 View →
Let's get this started! Über den Alltag als Arzt in Berlin. #cancer ...
Instagram

In der aktuellen Folge des Krebs-Podcasts sprechen Prof. Dr. Jalid Sehouli und Prof. Dr. Thorsten Schlomm über eine Frage, ...

Feb 1, 2022 View →
La doctora Marta Barrado desvela en su tesis doctoral en la UPNA ...
Facebook

... 10.1038/s41591-025-03961-8 Fuente: Ciencia, Astronomía y Afines · No photo description available. Deysi Querevalu Ramires and Golden Hawk. 2 ...

Aug 19, 2021 View →
Se aprobó el relugolix (Orgovyx) y esto influirá de inmediato en el ...
Facebook

Referencias: - "Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a ...

Apr 1, 2021 View →
El cáncer de próstata resistente a castración metastásico tiene un ...
Facebook

... 10.1038/s41591-025-03961-8 Fuente: Ciencia, Astronomía y Afines · لا يتوفر وصف للصورة. Deysi Querevalu Ramires وGolden Hawk. تفاعلان ·. مشاركة ...

Oct 2, 2020 View →
Estudiar los genes implicados en el desarrollo de ... - Facebook
Facebook

... 10.1038/s41591-025-03961-8 Fuente: Ciencia, Astronomía y Afines · No photo description available. Deysi Querevalu Ramires and Golden Hawk. 2 ...

Jun 11, 2020 View →
Un medicamento que ya tiene los permisos para el tratamiento de ...
Facebook

... 10.1038/s41591-025-03961-8 Fuente: Ciencia, Astronomía y Afines · No photo description available. Deysi Querevalu Ramires and Golden Hawk. 2 ...

Apr 29, 2020 View →
Sociedad Ecuatoriana de Oncología - Facebook
Facebook

Referencias: - "Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a ...

Mar 5, 2020 View →